In a double-blind, randomized, placebo controlled, parallel group study with a small group of patients (n = 8), over 4 weeks treatment of GSK239512 (a potent and selective H3R antagonist) displays a satisfactory level of tolerability and improved cognitive function in AD patients with mild to moderate symptoms [118]. Here, HRH3 is linked to Alzheimer disease.